Linwei Lu
Overview
Explore the profile of Linwei Lu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
416
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhou J, Meng N, Lu L, Lu J, Wu S, Ding Y, et al.
J Control Release
. 2024 Apr;
369:722-733.
PMID: 38583575
The existence of the blood-brain barrier (BBB) and blood-brain tumor barrier (BBTB) greatly limits the application of chemotherapy in glioma. To address this challenge, an optimal drug delivery system must...
2.
Ding Y, Xu Q, Chai Z, Wu S, Xu W, Wang J, et al.
J Control Release
. 2024 Apr;
369:325-334.
PMID: 38565395
Challenges for glioma treatment with nanomedicines include physio-anatomical barriers (the blood-brain barrier and blood-brain tumor barrier), low drug loading capacity, and limited circulation time. Here, a red blood cell membrane-coated...
3.
Zhang H, Liu Z, Lihe H, Lu L, Zhang Z, Yang S, et al.
Adv Healthc Mater
. 2023 Nov;
13(6):e2303261.
PMID: 37961920
Infectious disease pandemics, including the coronavirus disease 2019 pandemic, have heightened the demand for vaccines. Although parenteral vaccines induce robust systemic immunity, their effectiveness in respiratory mucosae is limited. Considering...
4.
Wang L, Wan F, Xu Y, Xie S, Zhao T, Zhang F, et al.
Nat Nanotechnol
. 2023 May;
18(9):1085-1093.
PMID: 37142709
High rates of ligament damage require replacements; however, current synthetic materials have issues with bone integration leading to implant failure. Here we introduce an artificial ligament that has the required...
5.
Luo Z, Wu S, Zhou J, Xu W, Xu Q, Lu L, et al.
Acta Pharm Sin B
. 2023 Feb;
13(1):359-371.
PMID: 36815053
Brain metastasis is a common and serious complication of breast cancer, which is commonly associated with poor survival and prognosis. In particular, the treatment of brain metastasis from triple-negative breast...
6.
Xu W, Yang S, Lu L, Xu Q, Wu S, Zhou J, et al.
J Control Release
. 2023 Jan;
354:538-553.
PMID: 36641120
Evidence is mounting that there is a significant gap between the antitumor efficacy of nanodrugs in preclinical mouse tumor models and in clinical human tumors, and that differences in tumor...
7.
Wang S, Wang R, Meng N, Lu L, Wang J, Zhou J, et al.
Acta Pharm Sin B
. 2022 Jul;
12(4):2000-2013.
PMID: 35847517
Thrombolytic agents have thus far yielded limited therapeutic benefits in the treatment of thrombotic disease due to their short half-life, low targeting ability, and association with serious adverse reactions, such...
8.
Lu L, Xu Q, Wang J, Wu S, Luo Z, Lu W
Pharmaceutics
. 2022 Apr;
14(4).
PMID: 35456631
Drug nanocrystals, which are comprised of active pharmaceutical ingredients and only a small amount of essential stabilizers, have the ability to improve the solubility, dissolution and bioavailability of poorly water-soluble...
9.
Luo Z, Lu L, Xu W, Meng N, Wu S, Zhou J, et al.
J Control Release
. 2022 Apr;
346:32-42.
PMID: 35378211
Chemotherapy is still the mainstay treatment for metastatic triple-negative breast cancers (TNBC) currently in clinical practice. The unmet needs of chemotherapy for metastatic TNBC are mainly from the insufficient drug...
10.
Wu S, Lu L, Zhou J, Ran D, Wang S, Xu Q, et al.
J Control Release
. 2022 Mar;
345:685-695.
PMID: 35346767
Glioblastoma (GBM) is the most aggressive brain tumor with poor prognosis and frequent recurrence. The blood-brain barrier (BBB), blood-brain tumor barrier (BBTB) hinder the entry of therapeutics into the glioma...